• Accumulated registered mums on the HeraMED platform at 4,398 as at 30 September 2025
• Successful $1.98 million capital raise completed during the quarter
• Significant progress toward two key U.S. commercial agreements

HeraMED Limited (ASX:HMD) reported its Quarterly Activities & Cashflow Report for the September 2025 quarter (Q3 FY25). Key highlights include: the number of accumulated registered mums on the HeraCARE platform reached 4,398 as at 30 September 2025; the company completed a successful $1.98 million capital raise during the quarter, extending its cash runway and supporting near-term U.S. commercial execution; significant progress was made toward two key U.S. commercial agreements, including a strategic partnership with a global health-technology leader and a direct deployment with a large U.S. health system; the company launched its AI & product strategy along with a roadmap with key development milestones across the AI Clinician Assistant, predictive-modelling and virtual-companion initiatives; HeraMED strengthened its Board with the appointment of Dr. Sharon Richardson Howell, a U.S.-based healthcare executive with extensive experience in population health, digital transformation and clinical-service innovation. As at 30 September 2025, the company had a cash balance of $1.77 million.

The U.S. remains HeraMED's focused market, with activity during the quarter centred on finalising two key commercial agreements and expanding the pipeline. The company is in advanced discussions with a global healthcare-technology leader to jointly offer an integrated remote-maternity-care solution, and is also in the final phase of contracting for a deployment with a major multi-hospital U.S. health-system based in Florida. Both agreements are expected to be executed in the near term and will represent a major step toward commercial scale in the U.S. market.